Pneumagen
Illetrop provides hands-on senior executive support to biotechnology companies. Based in Scotland but operating internationally, Illetrop represents a number of companies from the UK, Asia and mainland Europe including Pneumagen a company focused on developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs). Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Pneumagen has spun-off, through a demerger, a separate company called Omideon Limited. Omideon is focused on progressing the research and development of mCBMs in oncology . Please visit the website for more information. www.omideon.com
Contact Pneumagen via their website
News archive
08/03/2021 Pneumagen Announces Neumifil™ Efficacy in COVID-19 Infection Model...more
21/01/2021 Pneumagen Announces £2.5m fundraising for viral respiratory infection therapy...more
05/10/2020 Pneumagen‘s anti COVID-19 Neumifil featured in SCRIP‘s 10 to WATCH...more
16/09/2020 Pneumagen Announces Scientific Advisory Board and Development Team Appointments...more
27/05/2020 Pneumagen Announces £4m fundraising and Commits to Covid–19 Trial Development...more
08/05/2020 Pneumagen‘s Recent Covid–19 Data Covered by BBC‘s ”The Nine”...more
28/04/2020 PneumagenAnnounces Positive Anti–Viral Activity for Covid–19 Novel Glycan Approach...more
17/03/2020 Pneumagen Leverages Novel Glycan Approach to Target Covid–19...more
12/11/2019 Pneumagen Presents Poster on a Novel Preventative and Treatment of RSV...more
15/10/2019 Pneumagen Demonstrates Preclinical Proof–of–Concept in Oncology for Neumonco...more
